89bio, Inc. — Operating Income by Fiscal Year
7 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/8c4a99a9-35c9-4dc1-9854-7121843d60d9/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2024 | $-384.7M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-029243 |
| FY 2023 | $-151.2M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-024008 |
| FY 2022 | $-102.2M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-007929 |
| FY 2021 | $-89.7M | 2021-01-01 – 2021-12-31 | evidence 0001564590-22-011706 |
| FY 2020 | $-49.4M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-015214 |
| FY 2019 | $-26.6M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-011636 |
| FY 2018 | $-15.2M | 2018-01-18 – 2018-12-31 | evidence 0001564590-20-011636 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).